We are live on
!
Find out more
HM
HealthCor Management Portfolio holdings
AUM
$109M
1-Year Est. Return
10.64%
This Fund
S&P 500
This Quarter
Est. Return
+5.33%
1 Year Est. Return
+10.64%
3 Year Est. Return
+50.22%
5 Year Est. Return
+140.3%
10 Year Est. Return
–
AUM
$2.83B
AUM Growth
+$233M
(+9%)
Cap. Flow
+$131M
Cap. Flow
% of AUM
4.64%
Top 10 Holdings %
Top 10 Hldgs %
38.82%
Holding
108
New
54
Increased
16
Reduced
13
Closed
25
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Danaher
DHR
|
+$123M |
| 2 |
Incyte
INCY
|
+$96M |
| 3 |
Encompass Health
EHC
|
+$82.4M |
| 4 |
Petco
WOOF
|
+$73.5M |
| 5 |
Zoetis
ZTS
|
+$66.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Madrigal Pharmaceuticals
MDGL
|
+$100M |
| 2 |
Cooper Companies
COO
|
+$88.2M |
| 3 |
Aurinia Pharmaceuticals
AUPH
|
+$86.9M |
| 4 |
Bio-Rad Laboratories Class A
BIO
|
+$81.7M |
| 5 |
Bristol-Myers Squibb
BMY
|
+$80.5M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 83.85% |
| 2 | Real Estate | 4.52% |
| 3 | Consumer Discretionary | 2.42% |
| 4 | Financials | 1.56% |
| 5 | Technology | 1.15% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
CALL
Vertex Pharmaceuticals
VRTX
$123B
| $40.2M | 1.42% |
+187,000
| New | +$41.1M |
|
27
Align Technology
ALGN
$12B
| $38.7M | 1.37% |
+71,460
| New | +$39.5M |
|
28
CONMED
CNMD
$1.49B
| $36.2M | 1.28% |
276,940
+176,940
| +177% | +$21.3M |
|
29
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$818B
| $33.7M | 1.19% |
85,000
+10,000
| +13% | +$3.86M |
|
30
Guardant Health
GH
$21.1B
| $33.5M | 1.18% |
219,300
-323,860
| -60% | -$48.9M |
|
31
Elevance Health
ELV
$84.9B
| $32.9M | 1.17% |
+91,760
| New | +$29.5M |
|
|
NUAN
32
DELISTED
Nuance Communications, Inc.
NUAN
| $32.4M | 1.15% |
+742,030
| New | +$34.1M |
|
33
Halozyme
HALO
$10.2B
| $31.1M | 1.1% |
+745,605
| New | +$34M |
|
34
Syndax Pharmaceuticals
SNDX
$1.76B
| $30.7M | 1.09% |
1,371,480
+300,930
| +28% | +$6.8M |
|
35
PUT
iShares Russell 2000 ETF
IWM
$82.1B
| $29.8M | 1.06% |
135,000
+30,000
| +29% | +$6.55M |
|
36
PUT
Invesco QQQ Trust
QQQ
$479B
| $28.7M | 1.02% |
90,000
-50,000
| -36% | -$16M |
|
37
Royalty Pharma
RPRX
$25.4B
| $25.8M | 0.91% |
590,790
-748,740
| -56% | -$35.5M |
|
38
Ultragenyx Pharmaceutical
RARE
$2.55B
| $23.6M | 0.84% |
+207,610
| New | +$28.3M |
|
39
Acadia Pharmaceuticals
ACAD
$4.9B
| $23.2M | 0.82% |
+900,490
| New | +$39.6M |
|
40
Biogen
BIIB
$30.5B
| $22.5M | 0.8% |
80,510
+70,950
| +742% | +$19.1M |
|
41
Veeva Systems
VEEV
$35.4B
| $22.4M | 0.79% |
+85,900
| New | +$23.9M |
|
42
Sotera Health
SHC
$5.39B
| $20.1M | 0.71% |
+805,220
| New | +$21.3M |
|
|
LGV.U
43
DELISTED
Longview Acquisition Corp. II Units, each consisting of one share of Class A Common Stock and one-fifth of one redeemable Warrant
LGV.U
| $17.6M | 0.62% |
+1,750,000
| New | +$17.6M |
|
44
Allogene Therapeutics
ALLO
$680M
| $17.5M | 0.62% |
+494,640
| New | +$16.7M |
|
45
BioMarin Pharmaceuticals
BMRN
$11.9B
| $17.2M | 0.61% |
227,450
+5,240
| +2% | +$428K |
|
46
Haemonetics
HAE
$3.87B
| $16.5M | 0.58% |
148,480
-417,890
| -74% | -$51.7M |
|
47
Travere Therapeutics
TVTX
$5.89B
| $15.4M | 0.55% |
+618,520
| New | +$17.1M |
|
48
Arcus Biosciences
RCUS
$3.61B
| $15.1M | 0.53% |
+536,970
| New | +$18.7M |
|
49
eHealth
EHTH
$43.2M
| $13.1M | 0.46% |
+180,000
| New | +$11.5M |
|
|
AFMD
50
DELISTED
Affimed
AFMD
| $12.6M | 0.44% |
+158,794
| New | +$10.3M |
|
Similar funds
IA
EPC
TCMV
SI
HCWM
PC
RF
AWM
HealthCor Management's Q1 2021 Portfolio in Review
As of Q1 2021, HealthCor Management held 108 positions worth $2.83B, up 9% from $2.59B the previous quarter. Its ten largest holdings account for 39% of the portfolio.
HealthCor Management deployed $131M of net new capital in Q1 2021, opening 54 new positions and adding to 16 existing holdings. Its largest new stake was Danaher: 604,236 shares worth $121M.
By sector, the portfolio is most concentrated in Healthcare at 84% of assets, down from 92% a quarter earlier, followed by Real Estate and Consumer Discretionary.
On the sell side, the largest reduction was Cooper Companies, an estimated $88.2M trimmed.
- HealthCor Management's largest Q1 2021 buy was Danaher: 604,236 shares worth $121M.
- HealthCor Management added most to Incyte in Q1 2021, an estimated $96M increase.
- HealthCor Management's biggest Q1 2021 reduction was Cooper Companies, cutting an estimated $88.2M.
- HealthCor Management fully exited Madrigal Pharmaceuticals in Q1 2021, selling an estimated $100M.
- HealthCor Management's ten largest holdings make up 39% of its $2.83B portfolio in Q1 2021.
- HealthCor Management opened 54 new positions and closed 25 in Q1 2021.
- HealthCor Management's portfolio value rose 9% quarter-over-quarter to $2.83B.
Based on HealthCor Management's 13F filing for Q1 2021, filed 17 May 2021.